Eli Lilly announced an agreement to acquireVersanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases for $1.925B in cash.
Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese.
Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications.
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been selected for Innovate UK’s Global Incubator
Eli Lilly Acquires Obesity Drug Maker Versanis for $1.9B – M&A
by Fred Pennic Leave a Comment
What You Should Know:
SPY Stock analysis – Why the stock market & SPY Stock are selling off
SolasCure selected for innovate UK global incubator programme in houston
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been selected for Innovate UK’s Global Incubator
Study finds equal safety in home and birth center births
In low-risk pregnancies, mothers and children are just as safe with a planned home birth as they are with a planned birth center birth, a